Skip to main content
L

Not yet reviewed: this article is pending editorial review by Lyrea.

Citation noticeOur citation system is being overhauled

References and citation markers may currently be incomplete, mismatched, or incorrect. This system is being rebuilt and reviewed before the full site launch.

N-Ethylhexedrone

N-Ethylhexedrone molecule structureN-Ethylhexedrone molecule structure

N-Ethylhexedrone is a stimulant1 in the substituted cathinone class2 with a short duration of action.2 It was first synthesized by Boehringer Ingelheim in 19643 and appears to have entered the online research chemical market in late 2015. Users report euphoric effects resembling those of crack cocaine and α-PVP, particularly when snorted or vaporized. Recreational misuse is associated with compulsive redosing and addictive behavior.

Dosage & Duration

Dosage

Doses are population estimates that vary widely between individuals.

Threshold5-15 mg
Light15-25 mg
Moderate25-40 mg
Strong40-50 mg
Heavy50+ mg

Duration

Onset15-30 minutes
After Effects2-6 hours
Total1-4 hours

Subjective Effects

Subjective Effects not written up yet

Pharmacology

Pharmacodynamics

N-Ethylhexedrone inhibits dopamine and norepinephrine reuptake4, increasing their concentrations in the synapse by slowing their clearance. It inhibits the dopamine transporter more potently than the norepinephrine transporter, with reported IC50 values of 0.0467 μM and 0.0978 μM, respectively.5

Pharmacokinetics

Based on its structure and presumed similarity to other cathinones, N-Ethylhexedrone is likely metabolized through N-dealkylation or reduction of the carbonyl group followed by N-dealkylation.6

Metabolitesnone documented yet

Interactions

Interactions not written up yet

An unlisted combination is an unknown one, not a safe one. Check a dedicated combination chart before mixing.

Check TripSit

Tolerance

Tolerance timelines are rules of thumb, not exact schedules, and vary widely between individuals and use patterns.

Full Tolerance
Tolerance to many effects of N-ethylhexedrone develops with prolonged, repeated use, requiring larger doses to produce the same effects. Positive effects such as euphoria, improved concentration, sociability, and clearheadedness can begin fading within 30–60 minutes and may decline or disappear after a few redoses or with large amounts. The initial rush usually diminishes or disappears with repeated dosing and may not return with redosing, even while stimulation persists and adverse physical and mental effects increase.
Baseline Reset
Tolerance returns to baseline in approximately 1–2 weeks when no further N-ethylhexedrone is consumed.
Half Tolerance
Tolerance takes approximately 3–7 days to decrease by half when no further N-ethylhexedrone is consumed.
Cross Tolerance

Noradrenergic stimulants, Dopaminergic stimulants

Harm Potential

Addiction & Dependence

Psychological

Moderate

Chronic N-ethylhexedrone use is described as moderately addictive, with high abuse potential and psychological dependence in some users. Compulsive redosing can lead to excessive binges, including reported use lasting several days; repeated dosing may increasingly serve to avoid the comedown.

Physical

Cravings and unspecified withdrawal symptoms may occur when people who have developed addiction abruptly stop using N-ethylhexedrone.

Toxicity

Lethal Dosage

N-ethylhexedrone has been identified in post-mortem findings7 from overdose cases, without an established lethal-dose threshold. Its exact toxic dose is unknown.

Cardiovascular system

Observations and internet self-reports concerning N-ethylhexedrone include increased heart rate and blood pressure, abnormal heartbeat, and vasoconstriction, although effects are difficult to distinguish from those of co-administered substances.6

Nasal mucosa

Intranasal N-ethylhexedrone use has been associated with pain, nasal discharge, bleeding, and temporarily obstructed breathing; chronic intranasal use may cause tissue damage.

Nervous system

In a screening using cultured SH-SY5Y cells and yeast, N-ethylhexedrone appeared to have the greatest cytotoxicity among five tested cathinones.

Psychosis Risk

Compulsive N-ethylhexedrone use extending over several days without sleep is associated with a high chance of psychosis and paranoia. Psychotic symptoms generally appear after at least one missed night of sleep, although very heavy use within a single day can trigger paranoia and hallucinations.

Seizure Risk

N-ethylhexedrone is considered likely to increase seizure susceptibility, and people with epilepsy are advised to avoid it.

History & Culture

Early pharmaceutical development

N-Ethylhexedrone was first synthesized by the German pharmaceutical company Boehringer Ingelheim in 1964 and patented that year as a potential appetite suppressant. The patent described its synthesis alongside other aminoketone derivatives.6 It belonged to a series

Legality

International

1961 Single Convention on Narcotic Drugs: not scheduled; an exact-name and exact-identity search of the complete current INCB Yellow List found no N-ethylhexedrone (2-(ethylamino)-1-phenylhexan-1-one) entry.

1971 Convention on Psychotropic Substances: scheduled in Schedule II as N-ethylhexedrone; this confirms, rather than disproves, the packet's legacy Schedule II claim.

1988 United Nations Convention Against Illicit Traffic in Narcotic Drugs and Psychotropic Substances: not listed in either precursor Table I or Table II; an exact-name and exact-identity search of the complete current INCB Red List found no entry.

By Country

Illegal18
United States flagUnited StatesIllegal
Australia flagAustraliaIllegal
Austria flagAustriaIllegal
Brazil flagBrazilIllegal
Canada flagCanadaIllegal (analog/blanket ban)
Chile flagChileIllegal
Germany flagGermanyIllegal
Hungary flagHungaryIllegal
Ireland flagIrelandIllegal
Italy flagItalyIllegal
Japan flagJapanIllegal
Netherlands flagNetherlandsIllegal
Norway flagNorwayIllegal
Poland flagPolandIllegal
Singapore flagSingaporeIllegal
Sweden flagSwedenIllegal
Switzerland flagSwitzerlandIllegal
United Kingdom flagUnited KingdomIllegal (analog/blanket ban)
Controlled / restricted2
Colombia flagColombiaRestricted
Spain flagSpainRestricted

References

Citations

  1. Acute Pharmacological Effects of Two Synthetic Cathinones in Humans: An Observational Study of N-Ethylhexedrone and N-Ethyl-nor-pentedrone. Pharmaceuticals (2025). https://doi.org/10.3390/ph180507211
  2. Determination of N-ethylhexedrone, a new cathinone derivative, in blood collected from drivers – analysis of three cases. Problems of Forensic Sciences (2017). https://arch.ies.gov.pl/images/PDF/2017/vol_109/109_Adamowicz_m.pdf12
  3. Fatal N-Ethylhexedrone Intoxication. Journal of Analytical Toxicology (2021). https://academic.oup.com/jat/article/45/6/e1/59224721
  4. A review of synthetic cathinones emerging in recent years (2019–2022). Forensic Toxicology (2022). https://doi.org/10.1007/s11419-022-00639-51
  5. Structure-activity relationships of bath salt components: substituted cathinones and benzofurans at biogenic amine transporters. Psychopharmacology (2019). https://doi.org/10.1007/s00213-018-5059-512345
  6. Critical Review Report: N-Ethylhexedrone. World Health Organization (2019). https://ecddrepository.org/sites/default/files/2023-04/final_n-ethylhexedrone.pdf123
  7. Fatal intoxication with U-47700 in combination with other NPS (/N-ethylhexedrone, adinazolam, 4-CIC, 4-CMC) confirmed by identification and quantification in autopsy specimens and evidences. Forensic Toxicology (2021). https://doi.org/10.1007/s11419-020-00568-11
  8. Collaboration of the Joint Research Centre and European Customs Laboratories for the Identification of New Psychoactive Substances. Current Pharmaceutical Biotechnology (2018). https://doi.org/10.2174/138920101966618052312271712
  9. Decreto Supremo N° 867 (2007), art. 1, modificado por Decreto N° 298 (2018); Ley N° 20.000, art. 1. nuevo.leychile.cl (n.d.). https://nuevo.leychile.cl/servicios/Consulta/Exportar?exportar_con_notas_al_pie=False&exportar_con_notas_bcn=False&exportar_con_notas_originales=False&exportar_formato=pdf&hddResultadoExportar=1118582.2018-05-16.0.0%23&nombrearchivo=Decreto-298_16-MAY-2018&radioExportar=Normas1
  10. Decreto Supremo N° 867 (2007), art. 1, modificado por Decreto N° 298 (2018); Ley N° 20.000, art. 1. nuevo.leychile.cl (n.d.). https://nuevo.leychile.cl/servicios/Consulta/Exportar?exportar_con_notas_al_pie=True&exportar_con_notas_bcn=True&exportar_con_notas_originales=True&exportar_formato=pdf&hddResultadoExportar=269323.2023-09-16.0.0%23&nombrearchivo=DTO-867_19-FEB-2008&radioExportar=Normas1

Further Reading

  1. Nadal-Gratacós et al. 2023 - Structure–Activity Relationship of N -Ethyl-Hexedrone Analogues: Role of the α-Carbon Side-Chain Length in the Mechanism of Action, Cytotoxicity, and Behavioral Effects in Mice
  2. Gatch et al. 2020 - Behavioral effects of four novel synthetic cathinone analogs in rodents

Article Status

  • Josie Kins avatar
    Step 1 · Automated synthesis

    An autonomous workflow built by Josie Kins compiled this article's foundation from information published across the web.

  • Step 2 · First-pass reviewPending

    Not yet reviewed: this article is pending editorial review by Lyrea.

  • Step 3 · Citation reviewPending

    No one has reviewed this article's citations yet. That second pass checks each claim against the source it cites.

Suggest an edit

Spotted a mistake, an outdated claim, or something missing from the N-Ethylhexedrone article? Send the editors a private note. Feedback lands in a moderation queue and is never shown on the site.

Wish to give generalised feedback? You can do so here.